

IN THE CLAIMS:

Claims 2, 4, 5, 8, 9, and 11-16 are herein cancelled. Claims 1, 3, and 10 have been amended herein. New claim 17 is presented herein. All of the pending claims 1, 3, 6, 7, 10, and 17 are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

Listing of the Claims:

1. (Currently amended) A peptide ~~comprising~~ consisting of:
~~at least part of the amino acid sequence of SEQ ID NO:9~~ SEQ ID NO:1 wherein ~~an original the~~
amino acid at position 2 thereof is ~~substituted with~~ valine and
wherein said peptide is immunogenic with lymphocytes directed against metastatic melanomas.
2. (Canceled).
3. (Withdrawn and currently amended) The peptide of ~~claim 2 of claim 1~~, wherein the
~~original~~ amino acid at position 2, ~~threonine~~, is ~~substituted by a replacement amino acid~~ selected
from the group consisting of isoleucine, leucine, and valine.
- 4.-5. (Canceled).
6. (Original) A vaccine comprising the peptide of claim 1 or a nucleotide sequence
encoding said peptide.
7. (Original) The vaccine of claim 6, further comprising a pharmaceutically acceptable
carrier or diluent.
- 8.-9. (Canceled).

10. (Currently amended) The vaccine of claim 6, characterized in that it ~~also~~ further comprises one or more compounds selected from the group consisting of an adjuvant, one or more cytokines, antibodies directed against CD2, CD3, CD27, CD28 or other T cell surface ~~antigens~~ antigens, and helper epitopes to stimulate CD4+ or CD8+ T cells.

11.-16. (Canceled).

17. (New) A peptide consisting of:
the amino acid sequence of SEQ ID NO:1, wherein the amino acid at position 2 thereof may be
any amino acid and
wherein said peptide is immunogenic with lymphocytes directed against metastatic melanomas.